2011-08-012024-05-13https://scholars.lib.ntu.edu.tw/handle/123456789/649111摘要：本研究計畫之確切目標為研發出一種正子掃描製劑11C-PIB (Pittsburgh Compound B)，配合18F-FDG PET scan，希望能訂定分隔正常老年人、早期阿茲海默症(earlyAlzheimer’s disease; AD)，以及失憶型輕度知能障礙患者(patients with amnesic mild cognitive impairment)之核醫影像診斷條件。我們的工作包括放射性正子掃描試劑之研發，造影方法之設立，建立影像分析以及定量的準則。如此建立這個基礎之後，未來可以提供臨床醫師在MCI 與AD 病患長期追蹤病情、監控臨床療效，甚至作為開發治療AD 病患新藥的評估工具。本計畫期間之研究重點包括：第一年為11C-PIB 之研發、動物模式實驗(triple-mutation APPtransgenic mice, 6-8 隻)之進行以及提出人體試驗計畫送審；第二、三年則進行10 名50-85 歲之間心智功能正常者、20 名失憶型輕度知能障礙患者，20 名早期阿茲海默症患者，10 名其他類型失智症病患之11C-PIB, 18F-FDG PET 掃描。18F-FDG 掃描圖之分析以3D-SSP/NEUROSTAT (University of Seattle,WA, USA.)程式為之，以澳洲Austin Hospital in Melbourne 25 個平均為72 歲PIB 正子掃描正常，MRI正常而且神經精神分析也正常的人所構成的reference normal database 為參考，配合11C-PIB 在大腦皮質之攝取量，建立鑑別診斷之流程與定量分析之標準，以期未來可將11C-PIB 正子掃描作為失智症診斷的一種影像生物標記。<br> Abstract: The specific aim of this proposal is first to develop a PET radiopharmaceutical, i.e., 11C-PIB (PittsburghCompound B) for the diagnosis of Alzheimer’s disease(AD).We hope that in accompany with 18F-FDGPET scan, we can set up a diagnostic criteria by nuclear imaging to separate normal aging from earlyAlzheimer’s disease and the patients with amnesic mild cognitive impairment.We plan to synthesize thePET radiopharmaceutical, set up the protocol for imaging, the methods for image quantification and theprocedure guideline. By setting up this guideline, we can provide this imaging technique for the cliniciansfor long term follow up and monitoring of the progress of the disease and if possible, as a tool to evaluatethe effect of novel therapeutic agent for this disease.The main works for this research project will include:In the first year, we plan to synthesize and label the PIB with C-11 followed by animal study using 6-8triple-mutation APP transgenic mice with small animal PET scanner for validation.We will prepare andpass our clinical trial for the 2nd and 3rd year through the hospital IRB. In the 2nd and 3rd year, we will recruit10 normal aging people, 20 with MCI, 20 with AD and 10 with other types of dementia at the age ranging50-85. 11C-PIB and 18F-FDG PET will be performed in all these subjects after consensus. The3D-SSP/NEUROSTAT program from University of Seattle,WA, USA. will be used for image analyses. Thereference normal database from Austin Hospital in Melbourne of 25 people with average age of 72 years old,negative PIB PET scan, normal MRI and negative after neuropsychiatric screening will be used forcomparison. In accompany with the quantitative data from 11C-PIB PET scan we expect to set up ournormal range of image quantification and diagnostic sequence. We expect that 11C-PIB PET scan will oneday be used as the imaging biomarker for AD.